JP2009526861A5 - - Google Patents

Info

Publication number

JP2009526861A5

JP2009526861A5 JP2008555380A JP2008555380A JP2009526861A5 JP 2009526861 A5 JP2009526861 A5 JP 2009526861A5 JP 2008555380 A JP2008555380 A JP 2008555380A JP 2008555380 A JP2008555380 A JP 2008555380A JP 2009526861 A5 JP2009526861 A5 JP 2009526861A5

Authority

JP

Japan

Prior art keywords

seq

lec3

ednra

cxcr4

polypeptide

Prior art date

2007-02-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 102100036793 Adhesion G protein-coupled receptor L3 Human genes 0.000 claims 13
• 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 13
• 102000017914 EDNRA Human genes 0.000 claims 13
• 101000928176 Homo sapiens Adhesion G protein-coupled receptor L3 Proteins 0.000 claims 13
• 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 13
• 101000967336 Homo sapiens Endothelin-1 receptor Proteins 0.000 claims 13
• 238000000034 method Methods 0.000 claims 9
• 230000033115 angiogenesis Effects 0.000 claims 8
• 239000003937 drug carrier Substances 0.000 claims 8
• 229920001184 polypeptide Polymers 0.000 claims 8
• 108090000765 processed proteins & peptides Proteins 0.000 claims 8
• 102000004196 processed proteins & peptides Human genes 0.000 claims 8
• 150000001875 compounds Chemical class 0.000 claims 7
• 108091033319 polynucleotide Proteins 0.000 claims 7
• 102000040430 polynucleotide Human genes 0.000 claims 7
• 239000002157 polynucleotide Substances 0.000 claims 7
• 125000003275 alpha amino acid group Chemical group 0.000 claims 6
• 239000008194 pharmaceutical composition Substances 0.000 claims 5
• 239000013604 expression vector Substances 0.000 claims 4
• 230000000694 effects Effects 0.000 claims 3
• 239000000203 mixture Substances 0.000 claims 3
• 230000001737 promoting effect Effects 0.000 claims 3
• 230000001225 therapeutic effect Effects 0.000 claims 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
• 241000252212 Danio rerio Species 0.000 claims 2
• 241001465754 Metazoa Species 0.000 claims 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
• 230000008827 biological function Effects 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
• 101100074325 Caenorhabditis elegans lec-3 gene Proteins 0.000 claims 1
• 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 1
• 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 1
• 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
• 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 1
• 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 1
• 239000005557 antagonist Substances 0.000 claims 1
• 230000004071 biological effect Effects 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 150000007523 nucleic acids Chemical group 0.000 claims 1
• 239000002773 nucleotide Substances 0.000 claims 1
• 125000003729 nucleotide group Chemical group 0.000 claims 1